Regeneron Pharmaceuticals Inc (REGN)
NASDAQ · Healthcare · Biotechnology
Regeneron Pharmaceuticals Inc is a Healthcare company with a market capitalization of $80.55B, a trailing P/E ratio of 19.4, and a dividend yield of 0.45%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 29, 2026 | $9.47 | $8.90 | +6.4% |
| Q4 2025 | January 30, 2026 | $11.44 | $10.75 | +6.4% |
| Q3 2025 | October 28, 2025 | $11.83 | $9.64 | +22.7% |
| Q2 2025 | August 1, 2025 | $12.89 | $8.44 | +52.7% |
| Q1 2025 | April 29, 2025 | $8.22 | $8.48 | -3.1% |
| Q4 2024 | February 4, 2025 | $12.07 | $11.19 | +7.9% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 3,501,203 | 3.25% | 4.7 | +0.2% |
| June 30, 2026 | 3,494,420 | 3.24% | 2.9 | +5.8% |
| June 15, 2026 | 3,304,329 | 3.07% | 3.4 | +10.1% |
| May 29, 2026 | 3,001,968 | 2.79% | 2.0 | +8.0% |
| May 15, 2026 | 2,780,809 | 2.58% | 3.6 | -15.0% |
| April 30, 2026 | 3,270,341 | 3.04% | 4.1 | +15.1% |
| April 15, 2026 | 2,841,780 | 2.64% | 4.4 | +11.5% |
| March 31, 2026 | 2,548,311 | 2.37% | 4.2 | +4.0% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Regeneron Pharmaceuticals Inc's market cap?
As of August 13, 2026, Regeneron Pharmaceuticals Inc (REGN) has a market capitalization of $80.55B.
What is Regeneron Pharmaceuticals Inc's P/E ratio?
Regeneron Pharmaceuticals Inc trades at a trailing price-to-earnings (P/E) ratio of 19.4. Its forward P/E is 17.1.
Does Regeneron Pharmaceuticals Inc pay a dividend?
Yes — Regeneron Pharmaceuticals Inc pays a dividend yielding 0.45%, an annual payout of $3.64 per share.
What sector is REGN in?
Regeneron Pharmaceuticals Inc is in the Healthcare sector, specifically the Biotechnology industry.
What is Regeneron Pharmaceuticals Inc's short interest?
As of the July 15, 2026 FINRA settlement, 3,501,203 REGN shares were sold short, or 3.25% of shares outstanding. Days to cover: 4.7. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Regeneron Pharmaceuticals Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Regeneron Pharmaceuticals Inc reported revenue of $14.34B and net income of $4.50B.
Ask your own questions about REGN
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.